New diabetes drug MK-2828 passes early safety check in small trial
NCT ID NCT07089784
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 32 times
Summary
This early-stage study tested a new medicine called MK-2828 in 46 adults with type 2 diabetes. The main goal was to see if the drug is safe and well-tolerated. Researchers also measured how the drug moves through the body and whether it affects a marker of inflammation (hsCRP). This is a Phase 1 trial, so it focuses on safety and dosing, not yet on treating the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
AMR Clinical ( Site 0003)
Knoxville, Tennessee, 37920, United States
-
AMR Lexington ( Site 0012)
Lexington, Kentucky, 40509, United States
-
Advanced Pharma CR, LLC ( Site 0001)
Miami, Florida, 33147, United States
-
Alliance for Multispecialty Research, LLC ( Site 0013)
Kansas City, Missouri, 64114, United States
-
Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0009)
Springfield, Missouri, 65802, United States
-
California Clinical Trials Medical Group managed by PAREXEL ( Site 0008)
Glendale, California, 91206, United States
-
ICON Early Phase Services ( Site 0006)
San Antonio, Texas, 78209, United States
-
Jacksonville Center for Clinical Research ( Site 0002)
Jacksonville, Florida, 32216, United States
-
ProSciento Inc. ( Site 0004)
Chula Vista, California, 91911, United States
-
QPS Miami Research Associates ( Site 0005)
South Miami, Florida, 33143, United States
-
Velocity Clinical Research, Hallandale Beach ( Site 0010)
Hallandale, Florida, 33009, United States
Conditions
Explore the condition pages connected to this study.